160 related articles for article (PubMed ID: 16269595)
1. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET.
Kumar R; Loving VA; Chauhan A; Zhuang H; Mitchell S; Alavi A
J Nucl Med; 2005 Nov; 46(11):1819-24. PubMed ID: 16269595
[TBL] [Abstract][Full Text] [Related]
2. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes.
Mavi A; Urhan M; Yu JQ; Zhuang H; Houseni M; Cermik TF; Thiruvenkatasamy D; Czerniecki B; Schnall M; Alavi A
J Nucl Med; 2006 Sep; 47(9):1440-6. PubMed ID: 16954551
[TBL] [Abstract][Full Text] [Related]
3. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E
Clin Radiol; 2008 Nov; 63(11):1213-27. PubMed ID: 18929039
[TBL] [Abstract][Full Text] [Related]
4. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
5. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
Conrad GR; Sinha P
Nucl Med Commun; 2003 Nov; 24(11):1129-37. PubMed ID: 14569166
[TBL] [Abstract][Full Text] [Related]
6. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.
Beaulieu S; Kinahan P; Tseng J; Dunnwald LK; Schubert EK; Pham P; Lewellen B; Mankoff DA
J Nucl Med; 2003 Jul; 44(7):1044-50. PubMed ID: 12843218
[TBL] [Abstract][Full Text] [Related]
7. Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.
Imbriaco M; Caprio MG; Limite G; Pace L; De Falco T; Capuano E; Salvatore M
AJR Am J Roentgenol; 2008 Nov; 191(5):1323-30. PubMed ID: 18941064
[TBL] [Abstract][Full Text] [Related]
8. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.
Zhuang H; Pourdehnad M; Lambright ES; Yamamoto AJ; Lanuti M; Li P; Mozley PD; Rossman MD; Albelda SM; Alavi A
J Nucl Med; 2001 Sep; 42(9):1412-7. PubMed ID: 11535734
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
10. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
[TBL] [Abstract][Full Text] [Related]
11. Time course of tumor SUV in 18F-FDG PET of breast cancer: presentation of a simple model using a single reference point for time corrections of tumor SUVs.
Stahl AR; Heusner TA; Hartung V; Nagarajah J; Bockisch A; Hahn S; Antoch G; Jentzen W
J Nucl Med; 2011 Jan; 52(1):18-23. PubMed ID: 21149481
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of contrast medium enhancement and [(18)F]-FDG uptake of liver metastasis in PET/CT prior to therapy.
Hundt W; la Fougère C; Vogtmann J; Steinbach S; Burbelko M; Tiling R
Eur J Radiol; 2012 Apr; 81(4):652-7. PubMed ID: 21300504
[TBL] [Abstract][Full Text] [Related]
14. Background ¹⁸F-FDG uptake in positron emission mammography (PEM): correlation with mammographic density and background parenchymal enhancement in breast MRI.
Koo HR; Moon WK; Chun IK; Eo JS; Jeyanth JX; Chang JM; Cho N; Kang KW
Eur J Radiol; 2013 Oct; 82(10):1738-42. PubMed ID: 23806533
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
16. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules.
Matthies A; Hickeson M; Cuchiara A; Alavi A
J Nucl Med; 2002 Jul; 43(7):871-5. PubMed ID: 12097455
[TBL] [Abstract][Full Text] [Related]
17. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
18. Standardized uptake values of normal breast tissue with 2-deoxy-2-[F-18]fluoro-D: -glucose positron emission tomography: variations with age, breast density, and menopausal status.
Kumar R; Chauhan A; Zhuang H; Chandra P; Schnall M; Alavi A
Mol Imaging Biol; 2006; 8(6):355-62. PubMed ID: 17053861
[TBL] [Abstract][Full Text] [Related]
19. Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET.
Souvatzoglou M; Ziegler SI; Martinez MJ; Busch R; Dzewas G; Schwaiger M; Bengel F
Eur J Nucl Med Mol Imaging; 2007 Mar; 34(3):405-12. PubMed ID: 16953402
[TBL] [Abstract][Full Text] [Related]
20. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]